10-QPeriod: Q2 FY2024

DANAHER CORP /DE/ Quarterly Report for Q2 Ended Jun 28, 2024

Filed July 23, 2024For Securities:DHR

Summary

Danaher Corporation reported a 3.0% decrease in overall revenues for the second quarter of 2024 compared to the prior year, with core sales down 3.5%. This decline was primarily driven by weaker performance in the Biotechnology and Life Sciences segments, particularly in high-growth markets like China. Conversely, the Diagnostics segment showed resilience with increased core sales, led by North America. The company's net earnings from continuing operations also saw a year-over-year decrease, reflecting lower sales and increased other expenses. Despite the revenue headwinds, Danaher's gross profit margin improved due to lower cost of sales and the benefit from the Abcam acquisition. For the first six months of 2024, the trend of declining revenues and core sales continued, mirroring the quarterly performance. Operating profit margins across segments showed mixed results, with significant decreases in Life Sciences and Biotechnology, while Diagnostics saw substantial improvement. The company generated strong operating cash flows but utilized a significant portion for substantial stock repurchases during the period. Danaher maintained its focus on strategic investments and managing its capital structure, with liquidity expected to remain sufficient.

Financial Highlights

50 data points
Beta

Revenue

$5.74B

59.7% Gross Margin

Net Income

$907.00M

15.8% Net Margin

EPS (Diluted)

$1.22

Total Assets

$78.56B

Cash & Equivalents

$2.37B

Free Cash Flow

$1.13B

Financial Statements
Beta
Revenue$5.74B
Cost of Revenue$2.31B
Gross Profit$3.43B
R&D Expenses$391.00M
SG&A Expenses$1.87B
Operating Income$1.17B
Net Income$907.00M
EPS (Basic)$1.23
EPS (Diluted)$1.22
Shares Outstanding (Basic)737.60M
Shares Outstanding (Diluted)742.40M

Key Highlights

  • 1Overall revenues decreased by 3.0% year-over-year for the second quarter of 2024, with core sales down 3.5%, driven by weaknesses in Biotechnology and Life Sciences segments.
  • 2The Diagnostics segment demonstrated strength, with total sales up 1.5% and core sales up 3.0% in Q2 2024, driven by clinical diagnostics businesses.
  • 3Net earnings from continuing operations decreased to $907 million ($1.22/share) in Q2 2024 from $920 million ($1.24/share) in Q2 2023, attributed to lower core sales and increased expenses.
  • 4Gross profit margin improved to 59.7% in Q2 2024 from 56.1% in Q2 2023, benefiting from lower cost of sales and the Abcam acquisition.
  • 5Operating cash flow from continuing operations was $3.2 billion for the first six months of 2024, a decrease of 9% year-over-year.
  • 6Significant capital deployment was noted, with $4.5 billion spent on share repurchases in the first six months of 2024, alongside $0.4 billion in dividend payments.
  • 7The company highlights ongoing strategic investments and its robust liquidity position, expecting sufficient cash flow to fund operations, acquisitions, and shareholder returns.

Frequently Asked Questions

The primary driver for the 3.0% decrease in overall revenues and 3.5% decline in core sales for the second quarter of 2024 was weaker performance in the Biotechnology and Life Sciences segments. This was particularly impacted by reduced demand and customer inventory reductions in bioprocessing, as well as general demand weakness in mass spectrometry, flow cytometry, and microscopy businesses, especially in high-growth markets like China.

The acquisition of Abcam plc had a mixed impact. It contributed positively to gross profit margin improvement due to the inherent margin of the acquired business, but it also increased SG&A expenses as a percentage of sales due to associated amortization expenses. Additionally, an acquisition-related charge for the fair value adjustment to inventory related to Abcam increased cost of sales by $25 million in the six-month period.

The company noted that revenue declines in the Biotechnology segment moderated compared to the first quarter, as larger customers in the U.S. and Europe appear to have largely reduced excess inventory. They anticipate a gradual year-over-year improvement in demand for bioprocessing throughout the remainder of 2024. The Diagnostics segment continues to show strength and growth, while the Life Sciences segment faced challenges primarily related to equipment demand weakness.

Danaher has maintained a significant commitment to shareholder returns, executing substantial share repurchases totaling $4.5 billion in the first six months of 2024. Dividend payments also continued, though they decreased slightly compared to the prior year. The company emphasizes that its operating cash flow, cash on hand, and liquidity sources are expected to be sufficient to fund operations, strategic acquisitions, and shareholder returns.